Fintel reports that on August 15, 2023, RBC Capital downgraded their outlook for Design Therapeutics (NASDAQ:DSGN) from Outperform to Sector Perform.
Analyst Price Forecast Suggests 268.76% Upside
As of August 2, 2023, the average one-year price target for Design Therapeutics is 27.03. The forecasts range from a low of 19.19 to a high of $44.10. The average price target represents an increase of 268.76% from its latest reported closing price of 7.33.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Design Therapeutics is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.59.
What is the Fund Sentiment?
There are 223 funds or institutions reporting positions in Design Therapeutics. This is a decrease of 6 owner(s) or 2.62% in the last quarter. Average portfolio weight of all funds dedicated to DSGN is 0.11%, a decrease of 30.27%. Total shares owned by institutions increased in the last three months by 5.06% to 41,297K shares. The put/call ratio of DSGN is 0.17, indicating a bullish outlook.
What are Other Shareholders Doing?
Sr One Capital Management holds 6,526K shares representing 11.67% ownership of the company. No change in the last quarter.
Cormorant Asset Management holds 5,150K shares representing 9.21% ownership of the company. No change in the last quarter.
Avoro Capital Advisors holds 3,500K shares representing 6.26% ownership of the company. No change in the last quarter.
Ra Capital Management holds 2,971K shares representing 5.31% ownership of the company. No change in the last quarter.
Citadel Advisors holds 2,865K shares representing 5.12% ownership of the company. In it’s prior filing, the firm reported owning 2,503K shares, representing an increase of 12.66%. The firm decreased its portfolio allocation in DSGN by 39.38% over the last quarter.
Design Therapeutics Background Information
(This description is provided by the company.)
Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.
This article originally appeared on Fintel
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
